{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:58Z","timestamp":1787021458382,"version":"build-2736575974"},"update-to":[{"DOI":"10.12688\/f1000research.123040.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000}},{"DOI":"10.12688\/f1000research.123040.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000}}],"reference-count":32,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    Background Priapism induces regulation of Transforming Growth Factor-\u03b21 (TGF-\u03b21) expression and collagen-type-1 deposition. This will replace the normal corpora cavernosa with fibrotic tissue which eventually resulted in erectile dysfunction. It is also known that the fibrosis process of corpora cavernosa is related to Renin-Angiotensin II System (RAS). Angiotensin II receptor blockers (ARB), especially losartan, inhibit the inflammation process and fibrotic tissue formation. This study evaluated the effect of losartan in reducing fibrosis in priapism by evaluating TGF-\u03b21 and collagen-type-1 in cavernous tissue and determined the effect of losartan in preventing fibrosis in priapism model of Wistar rats assessed by the metavir score. Methods A total of eighteen male Wistar rats mean were divided into five groups. For the priapism models, we applied negative pressure on the penis to make an artificial erection to mimic the priapism process. The control groups were observed and the treatment groups were orally given losartan 15 mg\/kg\/day.\n                    <ns3:italic>Corpora cavernosa<\/ns3:italic>\n                    was harvested for TGF-\u03b21 and collagen-type-1 measurement using an enzyme-linked immunosorbent assay (ELISA). The fibrotic tissue of each rat was then collected and assessed histopathologically with the metavir scoring system. Results Penile TGF-\u03b21 concentration in the losartan-treated group was not significantly different on day 10 and day 28 of observation (p10=0,30; p28=0,17). Meanwhile, collagen-type-1 concentration was significantly lower compared to control group (p10=0,002; p28=0,01). There was a significant difference in metavir scores in rats that received losartan and those who did not (p&lt;0,05). Conclusion Losartan could suppress the fibrosis process in the priapism model. It could decrease the collagen type 1 deposition during\n                    <ns3:italic>corpora cavernosa<\/ns3:italic>\n                    tissue regeneration. Based on the metavir score, the group receiving losartan therapy was better than the control group.\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.123040.3","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:40:08Z","timestamp":1707212408000},"page":"831","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats"],"prefix":"10.12688","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-3671","authenticated-orcid":false,"given":"Safendra","family":"Siregar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-8686","authenticated-orcid":false,"given":"Rulianov","family":"Rulianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangga Adhazi","family":"Ksatriapraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-0767","authenticated-orcid":false,"given":"Dicky","family":"Stefanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"631-642","DOI":"10.1016\/j.ucl.2007.08.006","article-title":"Priapism: Current Principles and Practice.","volume":"34","author":"A Burnett","year":"2007","journal-title":"Urol. Clin. North Am."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"199-206","DOI":"10.21037\/tau.2017.01.18","article-title":"Advances in the understanding of priapism.","volume":"6","author":"M Hudnall","year":"2017","journal-title":"Transl. Androl. Urol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"476-500","DOI":"10.1111\/j.1743-6109.2009.01625.x","article-title":"Priapism: Pathogenesis, epidemiology, and management.","volume":"7","author":"G Broderick","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"838-841","DOI":"10.1111\/j.1464-410X.2009.08871.x","article-title":"Structural analysis of the corpora cavernosa in patients with ischaemic priapism.","volume":"105","author":"W Costa","year":"2010","journal-title":"BJU Int."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"760-764","DOI":"10.1016\/S0090-4295(03)00484-9","article-title":"Reperfusion of ischemic corporal tissue: Physiologic and biochemical changes in an animal model of ischemic priapism.","volume":"62","author":"R Munarriz","year":"2003","journal-title":"Urology."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2263-2266","DOI":"10.1016\/S0022-5347(01)62307-3","article-title":"Expression of TGF-\u03b2-1 mRNA and ultrastructural alterations in pharmacologically induced prolonged penile erection in a canine model.","volume":"160","author":"T Lue","year":"1998","journal-title":"J. Urol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1897-1914","DOI":"10.1517\/13543784.7.11.1897","article-title":"Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure.","volume":"7","author":"K Dickstein","year":"1998","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"393-400","DOI":"10.1097\/00004872-200502000-00022","article-title":"ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.","volume":"23","author":"K Yamamoto","year":"2005","journal-title":"J. Hypertens."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2909-2914","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.","volume":"108","author":"B Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"773-780","DOI":"10.1016\/S0168-8278(02)00307-0","article-title":"Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and\/or portal hypertension.","volume":"37","author":"V Croquet","year":"2002","journal-title":"J. Hepatol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"684-696","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis.","volume":"7","author":"Y Liu","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref35","first-page":"54-70","article-title":"Histological effects on the penile tissue of papaverine and combination of PPR (papaverine, prostaglandine, regitine) treated with intracavernosal injection (ICI) in the rats.","volume":"64","author":"S Turkan","year":"2014","journal-title":"Mitt. Klosterneubg."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"204-208","DOI":"10.1111\/bju.13717","article-title":"Guideline of guidelines: priapism.","volume":"119","author":"A Muneer","year":"2017","journal-title":"BJU Int."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"142-147","DOI":"10.1016\/S0022-5347(17)45549-2","article-title":"The ultrastucture of the erectile tissue in priapism.","volume":"135","author":"M Spycher","year":"1986","journal-title":"J. Urol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"492-497","DOI":"10.1038\/sj.ijir.3901261","article-title":"TGF-\u03b21 neutralizing antibodies decrease the fibrotic effects of ischemic priapism.","volume":"16","author":"O Sanli","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4195-4200","DOI":"10.1242\/jcs.023820","article-title":"The extracellular matrix at a glance.","volume":"123","author":"C Frantz","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1281-1292","DOI":"10.1016\/s0022-2828(05)82390-9","article-title":"Regulation of collagen degradation in the rat myocardium after infarction.","volume":"27","author":"J Cleutjens","year":"1995","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1189-1199","DOI":"10.1681\/ASN.2010040384","article-title":"Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis.","volume":"22","author":"C R\u00fcster","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1120-1131","DOI":"10.1152\/japplphysiol.00689.2014","article-title":"Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury.","volume":"117","author":"K Garg","year":"2014","journal-title":"J. Appl. Physiol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1197-1202","DOI":"10.1161\/01.HYP.35.6.1197","article-title":"Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis spontaneously hypertensive rats.","volume":"35","author":"N Varo","year":"2000","journal-title":"Hypertension."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"G726-G734","DOI":"10.1152\/ajpgi.00162.2009","article-title":"Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. American Journal of Physiology-Gastrointestinal and Liver.","volume":"297","author":"J Colmenero","year":"2009 Oct","journal-title":"Physiology."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1470320316628717","DOI":"10.1177\/1470320316628717","article-title":"Therapeutic effect of renin-angiotensin system inhibitors on liver fibrosis.","volume":"17","author":"Q Zhu","year":"2016 Feb 26","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.yjmcc.2007.07.040","article-title":"The novel angiotensin receptor blocker, telmisartan prevents myocardial hypertrophy and fibrosis in renovascular hypertensive (Goldblatt) rat.","volume":"2","author":"M Kawai","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"325-338","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis.","volume":"12","author":"X Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"863-873","DOI":"10.1016\/j.cellbi.2004.09.003","article-title":"Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro.","volume":"28","author":"C Zhang","year":"2004","journal-title":"Cell Biol. Int."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1-7","DOI":"10.1186\/s13069-015-0023-z","article-title":"Modulation of angiotensin II signaling in the prevention of fibrosis.","volume":"8","author":"A Murphy","year":"2015 Dec","journal-title":"Fibrogenesis Tissue Repair."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2909-2914","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.","volume":"108","author":"B Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"889-896","DOI":"10.1007\/s00535-008-2239-9","article-title":"Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model.","volume":"43","author":"M Kim","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2019-2028","DOI":"10.1053\/j.gastro.2007.09.023","article-title":"Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury.","volume":"133","author":"P Sancho-Bru","year":"2007","journal-title":"Gastroenterology."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"564-568","DOI":"10.1007\/s10620-010-1507-8","article-title":"The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort.","volume":"56","author":"B Abu Dayyeh","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1451-1453","DOI":"10.1513\/AnnalsATS.201903-198RL","article-title":"Angiotensin receptor blockers and subclinical interstitial lung disease: the MESA study.","volume":"16","author":"W Gannon","year":"2019 Nov","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.17632\/7dpb82y8j5.1","article-title":"The Role of Angiotensin Receptor Blocker (Losartan) on Decreasing Fibrotic Process of Corpora Cavernosa in Priapism Model of Wistar Rats.","volume":"V1","author":"S Siregar","year":"2022","journal-title":"Mendeley Data."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/11-831\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-831\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-831\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:40:13Z","timestamp":1707212413000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/11-831\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":32,"URL":"https:\/\/doi.org\/10.12688\/f1000research.123040.3","relation":{},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/11-831\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.135103.r150826, Widi Atmoko, Department of Urology, Faculty of Medicine, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, 03 Oct 2022, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/11-831\/v1#referee-response-150826","order":0,"name":"referee-response-150826","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Dicky Stefanus<\/b>; \n<i>Posted: 04 Oct 2022<\/i>; Thank you for the review, yes we hope this research will make a pilot study with larger sample to other research in the future,  Many thanks","URL":"https:\/\/f1000research.com\/articles\/11-831\/v3#referee-comment-8859","order":1,"name":"referee-comment-8859","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.135103.r154482, Guiting Lin, Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California San Francisco, San Francisco, CA, 21 Nov 2022, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/11-831\/v1#referee-response-154482","order":2,"name":"referee-response-154482","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Dicky Stefanus<\/b>; \n<i>Posted: 28 Apr 2023<\/i>; Greetings, I am very sorry for the late response.  This study uses the Federer formula to decide the minimum sample size of each group (4 animals).  In the normal control group (sham group) we only used 2 samples because we consider the animal welfare law from the Institutional Animal Care and Use Committee (IACUC) guidance. &nbsp; Group 1: sample 1.1, 1.2, 1.3, 1.4 (a model of priapism without therapy which was sacrificed on day ten)Group 2: sample 2.1, 2.2, 2.3, 2.4 (a model of priapism without treatment which was sacrificed on day 28). &nbsp; Group 3: sample 3.1, 3.2, 3.3, 3.4 (a model of priapism with the ARB losartan therapy sacrificed on day ten). &nbsp; Group 4: sample 4.1, 4.2, 4.3, 4.4 (a model of priapism with the ARB losartan therapy sacrificed on day 28). &nbsp; Group 5: sample 5.1, 5.2 (healthy controls). &nbsp; Full name of the abbreviation in this manuscript has been added when it appears for the first time. &nbsp; Tables 1 and 2 don\u2019t need statistical analysis. while Table 3-6 already have their respective statistical analysis results. &nbsp; Figures have been replaced with better resolutions images. &nbsp; Figure 3 has been revised as per the instructions. &nbsp; Figure 4 has been revised as per the instructions.","URL":"https:\/\/f1000research.com\/articles\/11-831\/v3#referee-comment-9618","order":3,"name":"referee-comment-9618","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.147597.r223719, David J. Ralph, Andrology Department, University College London Hospital, London, 30 Nov 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-831\/v2#referee-response-223719","order":4,"name":"referee-response-223719","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":5,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}